333 related articles for article (PubMed ID: 34204583)
1. Human α-Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease.
Modrego A; Amaranto M; Godino A; Mendoza R; Barra JL; Corchero JL
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204583
[TBL] [Abstract][Full Text] [Related]
2. Functional evaluation of a novel GLA causative mutation in Fabry disease.
Li P; Zhang L; Xiong Q; Wang Z; Cui X; Zhou YA; Wang Y; Xiao H; Wu C
Mol Genet Genomic Med; 2019 Sep; 7(9):e864. PubMed ID: 31321922
[TBL] [Abstract][Full Text] [Related]
3. Functional and Clinical Consequences of Novel α-Galactosidase A Mutations in Fabry Disease.
Lukas J; Scalia S; Eichler S; Pockrandt AM; Dehn N; Cozma C; Giese AK; Rolfs A
Hum Mutat; 2016 Jan; 37(1):43-51. PubMed ID: 26415523
[TBL] [Abstract][Full Text] [Related]
4. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.
Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM
EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984
[TBL] [Abstract][Full Text] [Related]
5. The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models.
Besada P; Gallardo-Gómez M; Pérez-Márquez T; Patiño-Álvarez L; Pantano S; Silva-López C; Terán C; Arévalo-Gómez A; Ruz-Zafra A; Fernández-Martín J; Ortolano S
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944500
[TBL] [Abstract][Full Text] [Related]
6. Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions.
Kok K; Zwiers KC; Boot RG; Overkleeft HS; Aerts JMFG; Artola M
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33673160
[TBL] [Abstract][Full Text] [Related]
7. Precision medicine in Fabry disease.
Lenders M; Brand E
Nephrol Dial Transplant; 2021 Jun; 36(Suppl 2):14-23. PubMed ID: 34153986
[TBL] [Abstract][Full Text] [Related]
8. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
Rosa Neto NS; Bento JCB; Pereira RMR
Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
[TBL] [Abstract][Full Text] [Related]
9. Genetics and Gene Therapy of Anderson-Fabry Disease.
Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic advances in Fabry disease: The future awaits.
Kant S; Atta MG
Biomed Pharmacother; 2020 Nov; 131():110779. PubMed ID: 33152937
[TBL] [Abstract][Full Text] [Related]
11. Treatment of fabry disease: current and emerging strategies.
Rozenfeld P; Neumann PM
Curr Pharm Biotechnol; 2011 Jun; 12(6):916-22. PubMed ID: 21235448
[TBL] [Abstract][Full Text] [Related]
12. Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates.
Zhu X; Yin L; Theisen M; Zhuo J; Siddiqui S; Levy B; Presnyak V; Frassetto A; Milton J; Salerno T; Benenato KE; Milano J; Lynn A; Sabnis S; Burke K; Besin G; Lukacs CM; Guey LT; Finn PF; Martini PGV
Am J Hum Genet; 2019 Apr; 104(4):625-637. PubMed ID: 30879639
[TBL] [Abstract][Full Text] [Related]
13. An Overview of Molecular Mechanisms in Fabry Disease.
Amodio F; Caiazza M; Monda E; Rubino M; Capodicasa L; Chiosi F; Simonelli V; Dongiglio F; Fimiani F; Pepe N; Chimenti C; Calabrò P; Limongelli G
Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291669
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Anderson-Fabry Disease.
Simonetta I; Tuttolomondo A; Daidone M; Miceli S; Pinto A
Curr Pharm Des; 2020; 26(40):5089-5099. PubMed ID: 32183665
[TBL] [Abstract][Full Text] [Related]
15. An expert consensus document on the management of cardiovascular manifestations of Fabry disease.
Linhart A; Germain DP; Olivotto I; Akhtar MM; Anastasakis A; Hughes D; Namdar M; Pieroni M; Hagège A; Cecchi F; Gimeno JR; Limongelli G; Elliott P
Eur J Heart Fail; 2020 Jul; 22(7):1076-1096. PubMed ID: 32640076
[TBL] [Abstract][Full Text] [Related]
16. Fabry disease: GLA deletion alters a canonical splice site in a family with neuropsychiatric manifestations.
Varela P; Carvalho G; Martin RP; Pesquero JB
Metab Brain Dis; 2021 Feb; 36(2):265-272. PubMed ID: 33156427
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Gene Variant Amenability for Pharmacological Chaperone Therapy with 1-Deoxygalactonojirimycin in Fabry Disease.
Lukas J; Cimmaruta C; Liguori L; Pantoom S; Iwanov K; Petters J; Hund C; Bunschkowski M; Hermann A; Cubellis MV; Rolfs A
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023956
[TBL] [Abstract][Full Text] [Related]
18.
Kytidou K; Beekwilder J; Artola M; van Meel E; Wilbers RHP; Moolenaar GF; Goosen N; Ferraz MJ; Katzy R; Voskamp P; Florea BI; Hokke CH; Overkleeft HS; Schots A; Bosch D; Pannu N; Aerts JMFG
J Biol Chem; 2018 Jun; 293(26):10042-10058. PubMed ID: 29674318
[TBL] [Abstract][Full Text] [Related]
19. Functional and pharmacological evaluation of novel GLA variants in Fabry disease identifies six (two de novo) causative mutations and two amenable variants to the chaperone DGJ.
Ferri L; Malesci D; Fioravanti A; Bagordo G; Filippini A; Ficcadenti A; Manna R; Antuzzi D; Verrecchia E; Donati I; Mignani R; Cavicchi C; Guerrini R; Morrone A
Clin Chim Acta; 2018 Jun; 481():25-33. PubMed ID: 29476735
[TBL] [Abstract][Full Text] [Related]
20. α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants.
Siekierska A; De Baets G; Reumers J; Gallardo R; Rudyak S; Broersen K; Couceiro J; Van Durme J; Schymkowitz J; Rousseau F
J Biol Chem; 2012 Aug; 287(34):28386-97. PubMed ID: 22773828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
